Page last updated: 2024-11-04

mepenzolate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4057
CHEMBL ID524004
CHEBI ID94411
SCHEMBL ID2994933
MeSH IDM0424551

Synonyms (64)

Synonym
CHEMBL524004
mepenzolate cation
mepenzolate ion
BRD-A62421304-004-05-6
KBIO1_000636
DIVK1C_000636
1-methyl-3-piperidyl benzilate methyl bromide
cantril
SPECTRUM_000985
PRESTWICK3_000653
BSPBIO_000685
PRESTWICK2_000653
NCGC00178896-01
NCGC00178896-02
SPECTRUM5_000948
(1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenyl-acetate
piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-
AB00053804
25990-43-6
mepenzolate
C07818
DB04843
mepenzolic acid
IDI1_000636
piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl- (van)
mepenzolon
piperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester)
KBIO2_006601
KBIOSS_001465
KBIO2_001465
KBIOGR_000503
KBIO2_004033
KBIO3_001459
PRESTWICK0_000653
SPECTRUM2_001042
SPBIO_002606
SPECTRUM4_000042
NINDS_000636
SPECTRUM3_000490
SPBIO_000964
PRESTWICK1_000653
BPBIO1_000755
BSPBIO_001959
glycophenylate
(1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
onw3lb39p7 ,
unii-onw3lb39p7
bdbm50377964
mepenzolate [who-dd]
piperidinium, 3-((hydroxydiphenylacetyl)oxy)-1,1-dimethyl-
mepenzolate [vandf]
3-(2-hydroxy(diphenyl)acetoxy)-1,1-dimethylpiperidinium
mepenzolate bromide free base [mi]
SCHEMBL2994933
DTXSID2046969
AB00053804_09
3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1,1-dimethylpiperidin-1-ium
2-hydroxy-2,2-diphenylacetic acid (1,1-dimethyl-3-piperidin-1-iumyl) ester
CHEBI:94411
SBI-0051436.P003
racemic mepenzolate
Q6817797
(plusmn)-mepenzolate
gtpl10470

Research Excerpts

Effects

ExcerptReferenceRelevance
"Mepenzolate has an asymmetric carbon atom, thus providing us with the opportunity to synthesize both of its enantiomers ((R)- and (S)-mepenzolate) and to examine their biochemical and pharmacological activities."( Synthesis and biological comparison of enantiomers of mepenzolate bromide, a muscarinic receptor antagonist with bronchodilatory and anti-inflammatory activities.
Asano, T; Fukunishi, Y; Hanaya, K; Ishihara, T; Kobayashi, D; Mashimo, T; Mizushima, T; Shoji, M; Sugai, T; Tanaka, K; Wada, M; Yamakawa, N; Yamashita, Y, 2014
)
1.37
"Mepenzolate has an asymmetric carbon atom, thus providing us with the opportunity to synthesize both of its enantiomers ((R)- and (S)-mepenzolate) and to examine their biochemical and pharmacological activities."( Synthesis and biological comparison of enantiomers of mepenzolate bromide, a muscarinic receptor antagonist with bronchodilatory and anti-inflammatory activities.
Asano, T; Fukunishi, Y; Hanaya, K; Ishihara, T; Kobayashi, D; Mashimo, T; Mizushima, T; Shoji, M; Sugai, T; Tanaka, K; Wada, M; Yamakawa, N; Yamashita, Y, 2014
)
1.37

Dosage Studied

ExcerptRelevanceReference
" Here, we show that cantils (previously known as nubbins) arise as one of the many phenotypic consequences of aneuploidy resulting from chromosome dosage imbalances in Arabidopsis polyaneuploids despite normal reproductive transition in long-day photoperiods."( Cantil - a new organ or a morphological oddity?
Bondada, R; Kulaar, DS; Maruthachalam, R; Siddiqi, I, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (42.86)18.7374
1990's2 (9.52)18.2507
2000's0 (0.00)29.6817
2010's7 (33.33)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.40 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]